PresolicitationActive75N98026Q00819CREAGENINC
synthesis of prodrug analogs and cyclopentane peptide nucleic acid (PNA) precursors
HEALTH AND HUMAN SERVICES, DEPARTMENT OF / NATIONAL INSTITUTES OF HEALTH / NATIONAL INSTITUTES OF HEALTH OLAOKey dates?
- Posted?
- Jul 16, 2026
- Response deadline?
- Jul 5, 2026, 1:00 PM UTC
- Archive date?
- —
- Archive type?
- autocustom
Classification?
- Notice type?
- Presolicitation
- Base type?
- Presolicitation
- Set-aside?
- No Set aside used
- Set-aside code?
- NONE
- PSC?
- 6505
NAICS?
Issuing office?
- Department?
- HEALTH AND HUMAN SERVICES, DEPARTMENT OF
- Sub-tier?
- NATIONAL INSTITUTES OF HEALTH
- Office?
- NATIONAL INSTITUTES OF HEALTH OLAO
- Office code?
- 075.7529.75N980
- Organization type?
- OFFICE
- Office address?
- BETHESDA, MD, 20892, USA
Place of performance?
- Street?
- —
- Street 2?
- —
- City?
- Bethesda
- State?
- Maryland
- Zip?
- 20892
- Country?
- UNITED STATES
Contacts?
- Vishnuvajjala Hanumanth Raoprimary
Description?
Background Information: The National Institute of Diabetes and Digestive and Kidney Diseases conducts and supports biomedical research to improve the understanding, prevention, and treatment of diseases affecting human health.? ? Within the Laboratory of Bioorganic Chemistry, the Synthetic Bioactive Molecules Section conducts research focused on the discovery and development of novel therapeutic compounds for the treatment and prevention of cancer and HIV infection. Ongoing studies have?identified?several promising?sulfanylbenzamide-derived compounds and?cyclopentane peptide?nucleic acid precursor materials with potential?applications?as anti-cancer therapeutics, HIV prevention and treatment agents, and diagnostic technologies.? ? To support these research efforts, the Synthetic Bioactive Molecules Section?requires?synthesis scale-up, custom synthesis, purification, and characterization of optimized lead compounds and specialized precursor materials. These materials are not commercially available and require specialized synthetic?expertise?and production capabilities to generate quantities sufficient for continued preclinical evaluation.? The materials produced under this requirement will be used in ongoing preclinical studies to evaluate compound activity,?optimize?lead candidates, and support advancement toward future clinical development.?
Attachments (1)?
- Download📎 Notice+of+Intent+-+VISHNU++CREAGEN+INC.docxapplication/octet-stream · 75 KB
Similar open contracts
Metadata?
- Notice ID?
- f91c144744ce480287dce66492d1ddf8
- Full path?
- HEALTH AND HUMAN SERVICES, DEPARTMENT OF.NATIONAL INSTITUTES OF HEALTH.NATIONAL INSTITUTES OF HEALTH OLAO
- Office code?
- 075.7529.75N980
- Ingested?
- Jul 17, 2026
- Updated?
- Jul 17, 2026